RESUMEN
Intensive research is devoted to unravel the neurobiological mechanisms mediating adult hippocampal neurogenesis, its regulation by antidepressants, and its behavioral consequences. Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that is expressed in the CNS, where its function is unknown. Here, we show, for the first time, the relevance of MIF expression for adult hippocampal neurogenesis. We identify MIF expression in neurogenic cells (in stem cells, cells undergoing proliferation, and in newly proliferated cells undergoing maturation) in the subgranular zone of the rodent dentate gyrus. A causal function for MIF in cell proliferation was shown using genetic (MIF gene deletion) and pharmacological (treatment with the MIF antagonist Iso-1) approaches. Behaviorally, genetic deletion of MIF resulted in increased anxiety- and depression-like behaviors, as well as of impaired hippocampus-dependent memory. Together, our studies provide evidence supporting a pivotal function for MIF in both basal and antidepressant-stimulated adult hippocampal cell proliferation. Moreover, loss of MIF results in a behavioral phenotype that, to a large extent, corresponds with alterations predicted to arise from reduced hippocampal neurogenesis. These findings underscore MIF as a potentially relevant molecular target for the development of treatments linked to deficits in neurogenesis, as well as to problems related to anxiety, depression, and cognition.
Asunto(s)
Antidepresivos de Segunda Generación/farmacología , Ansiedad/patología , Proliferación Celular/efectos de los fármacos , Depresión/patología , Fluoxetina/farmacología , Hipocampo/efectos de los fármacos , Factores Inhibidores de la Migración de Macrófagos/metabolismo , Trastornos de la Memoria/patología , Estimulación Acústica/efectos adversos , Animales , Antidepresivos de Segunda Generación/uso terapéutico , Ansiedad/tratamiento farmacológico , Ansiedad/genética , Bromodesoxiuridina/metabolismo , Proteína C-Reactiva/efectos de los fármacos , Proteína C-Reactiva/metabolismo , Condicionamiento Psicológico/efectos de los fármacos , Corticosterona/sangre , Corticosterona/uso terapéutico , Depresión/tratamiento farmacológico , Depresión/genética , Modelos Animales de Enfermedad , Miedo , Fluoxetina/uso terapéutico , Hipocampo/patología , Factores Inhibidores de la Migración de Macrófagos/deficiencia , Aprendizaje por Laberinto/efectos de los fármacos , Aprendizaje por Laberinto/fisiología , Trastornos de la Memoria/tratamiento farmacológico , Trastornos de la Memoria/genética , Ratones , Ratones Noqueados , Microscopía Confocal/métodos , Proteínas del Tejido Nervioso/efectos de los fármacos , Proteínas del Tejido Nervioso/metabolismo , Neurogénesis/efectos de los fármacos , Ratas , Ratas Wistar , Receptores de Esteroides/metabolismo , Conducta Espacial/efectos de los fármacosRESUMEN
Identification of new therapeutic targets for the management of septic shock remains imperative as all investigational therapies, including anti-tumor necrosis factor (TNF) and anti-interleukin (IL)-1 agents, have uniformly failed to lower the mortality of critically ill patients with severe sepsis. We report here that macrophage migration inhibitory factor (MIF) is a critical mediator of septic shock. High concentrations of MIF were detected in the peritoneal exudate fluid and in the systemic circulation of mice with bacterial peritonitis. Experiments performed in TNFalpha knockout mice allowed a direct evaluation of the part played by MIF in sepsis in the absence of this pivotal cytokine of inflammation. Anti-MIF antibody protected TNFalpha knockout from lethal peritonitis induced by cecal ligation and puncture (CLP), providing evidence of an intrinsic contribution of MIF to the pathogenesis of sepsis. Anti-MIF antibody also protected normal mice from lethal peritonitis induced by both CLP and Escherichia coli, even when treatment was started up to 8 hours after CLP. Conversely, co-injection of recombinant MIF and E. coli markedly increased the lethality of peritonitis. Finally, high concentrations of MIF were detected in the plasma of patients with severe sepsis or septic shock. These studies define a critical part for MIF in the pathogenesis of septic shock and identify a new target for therapeutic intervention.
Asunto(s)
Infecciones Bacterianas/prevención & control , Factores Inhibidores de la Migración de Macrófagos/antagonistas & inhibidores , Choque Séptico/prevención & control , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Animales , Infecciones Bacterianas/metabolismo , Femenino , Humanos , Factores Inhibidores de la Migración de Macrófagos/inmunología , Factores Inhibidores de la Migración de Macrófagos/metabolismo , Masculino , Ratones , Persona de Mediana Edad , Peritonitis/metabolismo , Peritonitis/prevención & control , Choque Séptico/metabolismoRESUMEN
To systematically examine the relation between motor milestone onset and disruption of night sleep in infancy, three families kept microgenetic, prospective, daily checklist diaries of their infants' motor behavior and sleep (197-313 observation days; 19,000 diary entries). Process control and interrupted time series analyses examined whether deviations from the moving average for night wakings and evening sleep duration were temporally linked to motor skill onset and tested for meaningful differences in individual sleep patterns before and after skill onset. Model assumptions defined skill onset as first day of occurrence or as mastery and moving average windows as 3, 7, or 14 days. Changes in infants' sleep patterns were associated with changing expertise for motor milestones. The temporal relation varied depending on infant and sleep parameter. Intensive longitudinal data collection may increase our understanding of micro-events in infant development.
Asunto(s)
Destreza Motora , Trastornos del Inicio y del Mantenimiento del Sueño , Niño , Humanos , Lactante , Estudios Prospectivos , Sueño , Factores de TiempoRESUMEN
For over 25 years, the cytokine known as macrophage migration inhibitory factor (MIF) has been considered to be a product of activated T lymphocytes. We recently identified the murine homolog of human MIF as a protein secreted by the pituitary in response to endotoxin administration. In the course of these studies, we also detected MIF in acute sera obtained from endotoxin-treated, T cell-deficient (nude), and hypophysectomized mice, suggesting that still more cell types produce MIF. Here, we report that cells of the monocyte/macrophage lineage are an important source of MIF in vitro and in vivo. We observed high levels of both preformed MIF protein and MIF mRNA in resting, nonstimulated cells. In the murine macrophage cell line RAW 264.7, MIF secretion was induced by as little as 10 pg/ml of lipopolysaccharide (LPS), peaked at 1 ng/ml, and was undetectable at LPS concentrations > 1 microgram/ml. A similar stimulation profile was observed in LPS-treated peritoneal macrophages; however, higher LPS concentrations were necessary to induce peak MIF production unless cells had been preincubated with interferon gamma (IFN-gamma). In RAW 264.7 macrophages, MIF secretion also was induced by tumor necrosis factor alpha (TNF-alpha) and IFN-gamma, but not by interleukins 1 beta or 6. Of note, MIF-stimulated macrophages were observed to secrete bioactive TNF-alpha. Although previously overlooked, the macrophage is both an important source and an important target of MIF in vivo. The activation of both central (pituitary) and peripheral (macrophage) sources of MIF production by inflammatory stimuli provides further evidence for the critical role of this cytokine in the systemic response to tissue invasion.
Asunto(s)
Factores Inhibidores de la Migración de Macrófagos/biosíntesis , Macrófagos/metabolismo , Animales , Secuencia de Bases , Western Blotting , Línea Celular , Cartilla de ADN , Femenino , Humanos , Hipofisectomía , Intrones , Cinética , Lipopolisacáridos/farmacología , Factores Inhibidores de la Migración de Macrófagos/análisis , Factores Inhibidores de la Migración de Macrófagos/farmacología , Macrófagos/efectos de los fármacos , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Datos de Secuencia Molecular , Especificidad de Órganos , Reacción en Cadena de la Polimerasa , Proteínas Recombinantes/farmacología , Linfocitos T/metabolismo , Factor de Necrosis Tumoral alfa/biosíntesisRESUMEN
30 years ago, investigations into the molecular basis of the delayed-type hypersensitivity reaction (DTH) provided evidence for the first lymphokine activity: a lymphocyte-derived mediator called macrophage migration inhibitory factor (MIF), which inhibited the random migration of peritoneal macrophages. Despite the long-standing association of MIF with the DTH reaction and the cloning of a human protein with macrophage migration inhibitory activity, the precise role of MIF in this classic cell-mediated immune response has remained undefined. This situation has been further complicated by the fact that two other cytokines, interferon gamma and IL-4, similarly inhibit macrophage migration and by the identification of mitogenic contaminants in some preparations of cloned human MIF. Using recently developed molecular probes for mouse MIF, we have examined the role of this protein in a classical model of DTH, the tuberculin reaction in mice. Both MIF messenger RNA and protein were expressed prominently in DTH lesions, as assessed by reverse transcription polymerase chain reaction, in situ hybridization, and immunostaining with anti-MIF antibody. The predominant cellular origin of MIF appeared to be the monocyte/macrophage, a cell type identified recently to be a major source of MIF release in vivo. The administration of neutralizing anti-MIF antibodies to mice inhibited significantly the development of DTH, thus affirming the central role of MIF in this classic immunological response.
Asunto(s)
Hipersensibilidad Tardía/etiología , Factores Inhibidores de la Migración de Macrófagos/metabolismo , Piel/inmunología , Tuberculina/inmunología , Animales , Secuencia de Bases , Femenino , Miembro Posterior/inmunología , Miembro Posterior/patología , Inmunohistoquímica , Hibridación in Situ , Factores Inhibidores de la Migración de Macrófagos/aislamiento & purificación , Macrófagos/metabolismo , Ratones , Ratones Endogámicos BALB C , Datos de Secuencia Molecular , Monocitos/metabolismo , ARN Mensajero/análisis , Piel/patologíaRESUMEN
An overproduction of proinflammatory cytokines by activated macrophages/monocytes mediates the injurious sequelae of inflammation, septic shock, tissue injury, and cachexia. We recently synthesized a tetravalent guanylhydrazone compound (CNI-1493) that inhibits cytokine-inducible arginine transport and nitric oxide (NO) production in macrophages, and protects mice against lethal endotoxemia and carrageenan-induced inflammation. During these investigations we noticed that CNI-1493 effectively prevented lipopolysaccharide (LPS)-induced NO production, even when added in concentrations 10-fold less than required to competitively inhibit L-arginine uptake, suggesting that the suppressive effects of this guanylhydrazone compound might extend to other LPS-induced responses. Here, we report that CNI-1493 suppressed the LPS-stimulated production of proinflammatory cytokines (tumor necrosis factor [TNF], interleukins 1beta and 6, macrophage inflammatory proteins 1alpha and 1beta) from human peripheral blood mononuclear cells. Cytokine suppression was specific, in that CNI-1493 did not inhibit either the constitutive synthesis of transforming growth factor beta or the upregulation of major histocompatibility complex class II by interferon gamma (IFN-gamma). In contrast to the macrophage suppressive actions of dexamethasone, which are overridden in the presence of IFN-gamma, CNI-1493 retained its suppressive effects even in the presence of IFN-gamma. The mechanism of cytokine-suppressive action by CNI-1493 was independent of extracellular L-arginine content and NO production and is not restricted to induction by LPS. As a selective inhibitor of macrophage activation that prevents TNF production, this tetravalent guanylhydrazone could be useful in the development of cytokine-suppressive agents for the treatment of diseases mediated by overproduction of cytokines.
Asunto(s)
Citocinas/biosíntesis , Hidrazonas/farmacología , Inflamación , Macrófagos/inmunología , Monocitos/inmunología , Óxido Nítrico Sintasa/biosíntesis , Animales , Línea Celular , Quimiocina CCL4 , Citocinas/antagonistas & inhibidores , Relación Dosis-Respuesta a Droga , Inducción Enzimática , Humanos , Interferón gamma/biosíntesis , Interleucina-1/biosíntesis , Interleucina-6/biosíntesis , Cinética , Lipopolisacáridos/antagonistas & inhibidores , Lipopolisacáridos/farmacología , Proteínas Inflamatorias de Macrófagos , Macrófagos/efectos de los fármacos , Ratones , Monocitos/efectos de los fármacos , Monocinas/biosíntesis , Óxido Nítrico/biosíntesis , Óxido Nítrico Sintasa/antagonistas & inhibidores , Factor de Necrosis Tumoral alfa/biosíntesisRESUMEN
High-dose cefepime therapy is recommended for febrile neutropenia. Safety issues have been raised in a recent meta-analysis reporting an increased risk of mortality during cefepime therapy. Cefepime-related neurological toxicity has been associated with overdosing due to severe renal dysfunction. This study aimed to investigate the association between cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients. Cefepime trough concentrations (by high-performance liquid chromatography) were retrospectively analyzed for 30 adult febrile neutropenic patients receiving the recommended high-dose regimen (6 g/day for a glomerular filtration rate [GFR] of >50 ml/min). The dose adjustment to renal function was evaluated by the ratio of the cefepime daily dose per 100 ml/min of glomerular filtration. The association between cefepime plasma concentrations and neurological toxicity was assessed on the basis of consistent neurological symptoms and/or signs (by NCI criteria). The median cefepime concentration was 8.7 mg/liter (range, 2.1 to 38 mg/liter) at a median of 4 days (range, 2 to 15 days) after the start of therapy. Neurological toxicity (altered mental status, hallucinations, or myoclonia) was attributed to cefepime in 6/30 (20%) patients (median GFR, 45 ml/min; range, 41 to 65 ml/min) receiving a median dose of 13.2 g/day per 100 ml/min GFR (range, 9.2 to 14.3 g/day per 100 ml/min GFR). Cefepime discontinuation resulted in complete neurological recovery for five patients and improvement for one patient. A multivariate logistic regression model confirmed high cefepime concentrations as an independent predictor of neurological toxicity, with a 50% probability threshold at ≥22 mg/liter (P = 0.05). High cefepime plasma concentrations are associated with neurological toxicity in febrile neutropenic patients with mild renal dysfunction. Careful adherence to normalized dosing per 100 ml/min GFR is crucial. Monitoring of plasma concentrations may contribute to preventing neurological toxicity of high-dose therapy for this life-threatening condition.
Asunto(s)
Cefalosporinas/uso terapéutico , Neutropenia/tratamiento farmacológico , Adulto , Anciano , Cefepima , Cefalosporinas/efectos adversos , Cefalosporinas/sangre , Femenino , Tasa de Filtración Glomerular/efectos de los fármacos , Alucinaciones/inducido químicamente , Humanos , Masculino , Persona de Mediana Edad , Sistema Nervioso/efectos de los fármacos , Neutropenia/sangre , Estudios RetrospectivosRESUMEN
The frequent lack of microbiological documentation of infection by blood cultures (BC) has a major impact on clinical management of febrile neutropenic patients, especially in cases of unexplained persistent fever. We assessed the diagnostic utility of the LightCycler SeptiFast test (SF), a multiplex blood PCR, in febrile neutropenia. Blood for BC and SF was drawn at the onset of fever and every 3 days of persistent fever. SF results were compared with those of BC, clinical documentation of infection, and standard clinical, radiological, and microbiological criteria for invasive fungal infections (IFI). A total of 141 febrile neutropenic episodes in 86 hematological patients were studied: 44 (31%) microbiologically and 49 (35%) clinically documented infections and 48 (34%) unexplained fevers. At the onset of fever, BC detected 44 microorganisms in 35/141 (25%) episodes. Together, BC and SF identified 78 microorganisms in 61/141 (43%) episodes (P = 0.002 versus BC or SF alone): 12 were detected by BC and SF, 32 by BC only, and 34 by SF only. In 19/52 (37%) episodes of persistent fever, SF detected 28 new microorganisms (7 Gram-positive bacterial species, 15 Gram-negative bacterial species, and 6 fungal species [89% with a clinically documented site of infection]) whereas BC detected only 4 pathogens (8%) (P = 0.001). While BC did not detect fungi, SF identified 5 Candida spp. and 1 Aspergillus sp. in 5/7 probable or possible cases of IFI. Using SeptiFast PCR combined with blood cultures improves microbiological documentation in febrile neutropenia, especially when fever persists and invasive fungal infection is suspected. Technical adjustments may enhance the efficiency of this new molecular tool in this specific setting.
Asunto(s)
Bacterias/aislamiento & purificación , Infecciones Bacterianas/diagnóstico , Sangre/microbiología , Fiebre de Origen Desconocido/complicaciones , Hongos/aislamiento & purificación , Micosis/diagnóstico , Reacción en Cadena de la Polimerasa/métodos , Adolescente , Adulto , Anciano , Bacterias/genética , Bacterias/crecimiento & desarrollo , Femenino , Hongos/genética , Hongos/crecimiento & desarrollo , Humanos , Huésped Inmunocomprometido , Masculino , Técnicas Microbiológicas/métodos , Persona de Mediana Edad , Neutropenia/complicaciones , Adulto JovenRESUMEN
Imipenem plasma concentrations were analyzed in 57 febrile neutropenic patients using the NONMEM program. The recommended 2-g/day regimen achieved coverage of the most common bacteria (MIC(90) = 1 mg/liter) during the whole dosing interval in only 53% of patients. This goal was achieved in 90% of patients with 3 g/day.
Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Neoplasias Hematológicas/complicaciones , Imipenem/administración & dosificación , Imipenem/uso terapéutico , Neutropenia/inducido químicamente , Neutropenia/complicaciones , Adolescente , Adulto , Anciano , Antibacterianos/farmacocinética , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Femenino , Tasa de Filtración Glomerular , Guías como Asunto , Neoplasias Hematológicas/tratamiento farmacológico , Humanos , Imipenem/farmacocinética , Masculino , Persona de Mediana Edad , Modelos Biológicos , Adulto JovenRESUMEN
Multiple approaches utilizing viral and DNA vectors have shown promise in the development of an effective vaccine against HIV. In this study, an alternative replication-defective flavivirus vector, RepliVax (RV), was evaluated for the delivery of HIV-1 immunogens. Recombinant RV-HIV viruses were engineered to stably express clade C virus Gag and Env (gp120TM) proteins and propagated in Vero helper cells. RV-based vectors enabled efficient expression and correct maturation of Gag and gp120TM proteins, were apathogenic in a sensitive suckling mouse neurovirulence test, and were similar in immunogenicity to recombinant poxvirus NYVAC-HIV vectors in homologous or heterologous prime-boost combinations in mice. In a pilot NHP study, immunogenicity of RV-HIV viruses used as a prime or boost for DNA or NYVAC candidates was compared to a DNA prime/NYVAC boost benchmark scheme when administered together with adjuvanted gp120 protein. Similar neutralizing antibody titers, binding IgG titers measured against a broad panel of Env and Gag antigens, and ADCC responses were observed in the groups throughout the course of the study, and T cell responses were elicited. The entire data demonstrate that RV vectors have the potential as novel HIV-1 vaccine components for use in combination with other promising candidates to develop new effective vaccination strategies.
Asunto(s)
Vacunas contra el SIDA/inmunología , Virus Defectuosos/genética , Flavivirus/genética , Vectores Genéticos , VIH-1/inmunología , Vacunas Sintéticas/inmunología , Animales , Anticuerpos Neutralizantes/inmunología , Chlorocebus aethiops , Reacciones Cruzadas , Femenino , Infecciones por VIH/virología , VIH-1/patogenicidad , Macaca mulatta , Ratones , Ratones Endogámicos BALB C , Células Vero , VirulenciaRESUMEN
Macrophage migration inhibitory factor (MIF) has recently been implicated in the pathogenesis of malarial anaemia. However, field studies have reported contradictory results on circulating MIF concentrations in patients with clinically overt Plasmodium falciparum malaria. We determined plasma MIF levels over time in 10 healthy volunteers during experimental P. falciparum infection. Under fully controlled conditions, MIF levels decreased significantly during early blood-stage infection and reached a nadir at day 8 post-infection. A decrease in the number of circulating lymphocytes, which are an important source of MIF production, paralleled the decrease in MIF levels. Monocyte/macrophage counts remained unchanged. At MIF nadir, the anti-inflammatory cytokine interleukin (IL)-10, which is an inhibitor of T-cell MIF production, was detectable in only 2 of 10 volunteers. Plasma concentrations of the pro-inflammatory cytokines IL-8 and IL-1beta were only marginally elevated. We conclude that circulating MIF levels decrease early in blood-stage malaria as a result of the decline in circulating lymphocytes.
Asunto(s)
Linfocitos/sangre , Factores Inhibidores de la Migración de Macrófagos/sangre , Malaria Falciparum/parasitología , Plasmodium falciparum/inmunología , Adolescente , Adulto , Animales , Femenino , Humanos , Interleucina-10/sangre , Interleucina-1beta/sangre , Interleucina-8/sangre , Recuento de Linfocitos , Macrófagos/inmunología , Malaria Falciparum/inmunología , Masculino , Monocitos/inmunología , Factores de TiempoRESUMEN
Immediate broad-spectrum empirical antibacterial therapy is the key of management in febrile neutropenic patients. These patients can be stratified according to the risk of complications with the clinical MASCC score. Patients at low risk of complications can be efficaciously treated with oral antibiotics (e.g. fluoroquinolone and beta-lactam), provided that compliance and drug absorption are adequate. Early discharge is possible if clinical, logistic, and social criteria are fulfilled. Intravenous antibiotic therapy with broad-spectrum beta-lactam antibiotics in the hospital remains the standard in high-risk patients. The empirical addition of an aminoglycoside and/or a glycopeptide is recommended if the local incidence of infections due to beta-lactam resistant pathogens is high or in critically ill septic patients.
Asunto(s)
Antibacterianos/uso terapéutico , Fiebre/tratamiento farmacológico , Neutropenia/tratamiento farmacológico , Humanos , Alta del Paciente , Selección de PacienteRESUMEN
BACKGROUND: Our current understanding of the pathophysiology and management of sepsis is associated with a lack of progress in clinical trials, which partly reflects insufficient appreciation of the heterogeneity of this syndrome. Consequently, more patient-specific approaches to treatment should be explored. AIMS: To summarize the current evidence on precision medicine in sepsis, with an emphasis on translation from theory to clinical practice. A secondary objective is to develop a framework enclosing recommendations on management and priorities for further research. SOURCES: A global search strategy was performed in the MEDLINE database through the PubMed search engine (last search December 2017). No restrictions of study design, time, or language were imposed. CONTENT: The focus of this Position Paper is on the interplay between therapies, pathogens, and the host. Regarding the pathogen, microbiologic diagnostic approaches (such as blood cultures (BCs) and rapid diagnostic tests (RDTs)) are discussed, as well as targeted antibiotic treatment. Other topics include the disruption of host immune system and the use of biomarkers in sepsis management, patient stratification, and future clinical trial design. Lastly, personalized antibiotic treatment and stewardship are addressed (Fig. 1). IMPLICATIONS: A road map provides recommendations and future perspectives. RDTs and identifying drug-response phenotypes are clear challenges. The next step will be the implementation of precision medicine to sepsis management, based on theranostic methodology. This highly individualized approach will be essential for the design of novel clinical trials and improvement of care pathways.
Asunto(s)
Medicina de Precisión/métodos , Sepsis/tratamiento farmacológico , Antibacterianos/uso terapéutico , Macrodatos , Biomarcadores , Ensayos Clínicos como Asunto , Manejo de la Enfermedad , Humanos , Microbiota/efectos de los fármacos , Pobreza , Sepsis/diagnóstico , Sepsis/microbiología , Sepsis/fisiopatología , Nanomedicina Teranóstica/métodosRESUMEN
BACKGROUND: Mannose-binding lectin (MBL) is a serum lectin involved in innate immune response. Low serum MBL concentration may constitute a risk factor for infection in patients receiving myelosuppressive chemotherapy. METHODS: We conducted a prospective, observational study that assessed MBL concentration as a risk factor for infection in patients with hematological malignancy who were hospitalized to undergo at least 1 chemotherapy cycle. MBL deficiency was defined using an algorithm that considered the serum MBL concentration and the MBL genotype. The primary end point was the ratio of duration of febrile neutropenia to the duration of neutropenia. Secondary end points included the incidence of severe infection (e.g., sepsis, pneumonia, bacteremia, and invasive fungal infection). Logistic regression analysis was conducted, and Fisher's exact test was used to analyze binary outcomes, and Kaplan-Meier estimates and log rank tests were used for time-to-event variables. RESULTS: We analyzed 255 patients who received 569 cycles of chemotherapy. The median duration of neutropenia per cycle was 7 days (interquartile range, 0-13 days). Sixty-two patients (24%) were found to have MBL deficiency. Febrile neutropenia occurred at least once in 200 patients. No difference in the primary outcome was seen. The incidence of severe infection was higher among MBL-deficient patients than among non-MBL-deficient patients (1.96 vs. 1.34 cases per 100 days for analysis of all patients [P=.008] and 1.85 vs. 0.94 cases per 100 days excluding patients with acute leukemia [P<.001]). CONCLUSIONS: MBL deficiency does not predispose adults with hematological cancer to more-frequent or more-prolonged febrile episodes during myelosuppressive chemotherapy, but MBL-deficient patients have a greater number of severe infections and experience their first severe infection earlier, compared with nondeficient patients.
Asunto(s)
Antineoplásicos/efectos adversos , Susceptibilidad a Enfermedades/sangre , Lectina de Unión a Manosa/sangre , Lectina de Unión a Manosa/deficiencia , Neumonía/sangre , Sepsis/sangre , Adulto , Anciano , Susceptibilidad a Enfermedades/inmunología , Femenino , Neoplasias Hematológicas/complicaciones , Neoplasias Hematológicas/tratamiento farmacológico , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Neutropenia/inducido químicamente , Neumonía/inmunología , Estudios Prospectivos , Factores de Riesgo , Sepsis/inmunologíaRESUMEN
Severe infection or tissue invasion can provoke a catabolic response, leading to severe metabolic derangement, cachexia, and even death. Macrophage migration inhibitory factor (MIF) is an important regulator of the host response to infection. Released by various immune cells and by the anterior pituitary gland, MIF plays a critical role in the systemic inflammatory response by counterregulating the inhibitory effect of glucocorticoids on immune-cell activation and proinflammatory cytokine production. We describe herein an unexpected role for MIF in the regulation of glycolysis. The addition of MIF to differentiated L6 rat myotubes increased synthesis of fructose 2,6-bisphosphate (F2,6BP), a positive allosteric regulator of glycolysis. Increased expression of the enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2) enhanced F2,6BP production and, consequently, cellular lactate production. The catabolic effect of TNF-alpha on myotubes was mediated by MIF, which served as an autocrine stimulus for F2, 6BP production. TNF-alpha administered to mice decreased serum glucose levels and increased muscle F2,6BP levels; pretreatment with a neutralizing anti-MIF mAb completely inhibited these effects. Anti-MIF also prevented hypoglycemia and increased muscle F2,6BP levels in TNF-alpha-knockout mice that were administered LPS, supporting the intrinsic contribution of MIF to these inflammation-induced metabolic changes. Taken together with the recent finding that MIF is a positive, autocrine stimulator of insulin release, these data suggest an important role for MIF in the control of host glucose disposal and carbohydrate metabolism.
Asunto(s)
Fructosadifosfatos/biosíntesis , Glucosa/metabolismo , Ácido Láctico/biosíntesis , Factores Inhibidores de la Migración de Macrófagos/metabolismo , Animales , Línea Celular , Movimiento Celular/fisiología , Glucólisis/efectos de los fármacos , Humanos , Hígado/metabolismo , Factores Inhibidores de la Migración de Macrófagos/farmacología , Macrófagos/metabolismo , Ratones , Músculos/metabolismo , Fosfofructoquinasa-2 , Monoéster Fosfórico Hidrolasas/metabolismo , Fosfotransferasas (Aceptor de Grupo Alcohol)/metabolismo , Ratas , Células Tumorales Cultivadas , Factor de Necrosis Tumoral alfa/farmacologíaAsunto(s)
Farmacorresistencia Bacteriana Múltiple/fisiología , Infecciones por Enterobacteriaceae/complicaciones , Infecciones por Escherichia coli/complicaciones , Gastroenteritis/etiología , Intestinos/microbiología , Simbiosis/fisiología , Enterobacteriaceae/genética , Enterobacteriaceae/metabolismo , Enterobacteriaceae/patogenicidad , Enterobacteriaceae/fisiología , Infecciones por Enterobacteriaceae/epidemiología , Infecciones por Enterobacteriaceae/microbiología , Escherichia coli/patogenicidad , Escherichia coli/fisiología , Infecciones por Escherichia coli/epidemiología , Infecciones por Escherichia coli/microbiología , Gastroenteritis/epidemiología , Gastroenteritis/microbiología , Humanos , Incidencia , Intestinos/fisiología , Intestinos/fisiopatología , Infecciones por Klebsiella/epidemiología , Infecciones por Klebsiella/etiología , Infecciones por Klebsiella/microbiología , Vida , Metagenoma/fisiología , Simbiosis/inmunología , Infecciones Urinarias/epidemiología , Infecciones Urinarias/etiología , Infecciones Urinarias/microbiología , Resistencia betalactámica/genética , beta-Lactamasas/genética , beta-Lactamasas/metabolismo , beta-Lactamasas/fisiologíaRESUMEN
Two thirds of the exacerbations of chronic obstructive pulmonary disease (COPD) are caused by infections of the respiratory tract. The causative microorganisms differ according to the degree of COPD severity, previous antibiotic therapy and prior bacterial infections. Antibiotics and intensification of bronchodilator therapy are the cornerstones of the management of moderate and severe exacerbations of COPD. Prompt therapy of COPD exacerbations has been shown to reduce the likelihood of hospitalisation and improve the quality of life. In this article, we have reviewed current recommendations regarding the use of antibiotics in the treatment of COPD exacerbations.